Catabasis Pharmaceuticals clinical trials
Acquired by BioCryst Pharmaceuticals, Jan 23, 2026 · source ↗
The registry lists 13 studies whose lead sponsor is Catabasis Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 23, 2022.
Before and after it joined BioCryst Pharmaceuticals
- First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- 13
- First submitted after Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Catabasis Pharmaceuticals13 studies
Something wrong with this grouping? Tell us on the BioCryst Pharmaceuticals page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All BioCryst Pharmaceuticals studies →
- Phase 1/2 Study in Boys With Duchenne Muscular DystrophyCompletedNCT02439216Phase 1/2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- Phase III Study of Edasalonexent in Boys With Duchenne Muscular DystrophyCompletedNCT03703882Phase 3
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- Study of Edasalonexent With Midazolam and Deflazacort in Healthy SubjectsCompletedNCT04543370Phase 1
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy SubjectsCompletedNCT02374047Phase 1
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular DystrophyTerminatedNCT03917719Phase 3
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With HypercholesterolemiaCompletedNCT02608697Phase 2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- Pilot Study To Assess CAT-2003 in Patients With HyperlipidemiaCompletedNCT01912560Phase 2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- Pilot Study To Assess CAT-2003 in Patients With ChylomicronemiaCompletedNCT02098278Phase 2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- Pilot Study To Assess CAT-2003 in Patients With Severe HypertriglyceridemiaCompletedNCT01968720Phase 2
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003CompletedNCT01725594Phase 1
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- A Study of CAT-1004 Biomarkers in Healthy SubjectsCompletedNCT01670773Phase 1
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 DiabetesCompletedNCT01511900Phase 1
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals
- Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult VolunteersCompletedNCT01440166Phase 1
Sponsor listed in the registry: Catabasis Pharmaceuticals · First submitted before Catabasis Pharmaceuticals became part of BioCryst Pharmaceuticals